Why the study?
Can serum lncRNAs NEAT1 and Lnc-DC differentiate childhood ITP patients from healthy controls and non-chronic from chronic ITP?
Can serum lncRNAs NEAT1 and Lnc-DC differentiate childhood ITP patients from healthy controls and non-chronic from chronic ITP?
Serum lncRNAs NEAT1 and Lnc-DC may serve as potential biomarkers for diagnosing and staging pediatric immune thrombocytopenic purpura.
Hypothesis-generating for lncRNA biomarkers in pediatric ITP; prospective validation needed before any clinical adoption.
serum lncRNAs, NEAT1 and Lnc-DC could be used as potential biomarkers in differentiating childhood ITP patients and healthy controls in addition to differentiating non-chronic from chronic ITP which may provide a theoretical basis for the mechanism and treatment of immune thrombocytopenia.
No takes yet. Share an insight, caveat, or question.
Hamdy et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: